NasdaqGS:INDVPharmaceuticals
Could Indivior (INDV) Turn Correctional Staffing Efficiencies Into a Durable Competitive Edge?
Indivior Pharmaceuticals recently reported that a new cost impact model, published in The Journal of Current Medical Research and Opinion, found its monthly injectable SUBLOCADE® could significantly reduce staff time and related costs for treating opioid use disorder in U.S. jails and prisons versus other medication options.
The study’s suggestion that extended-release buprenorphine may ease operational burdens in correctional healthcare could influence policymakers and institutional buyers...